158 related articles for article (PubMed ID: 19669207)
1. Genomic deletion and promoter methylation status of Hypermethylated in Cancer 1 (HIC1) in mantle cell lymphoma.
Stöcklein H; Hutter G; Kalla J; Hartmann E; Zimmermann Y; Katzenberger T; Adam P; Leich E; Höller S; Müller-Hermelink HK; Rosenwald A; Ott G; Dreyling M
J Hematop; 2008 Sep; 1(2):85-95. PubMed ID: 19669207
[TBL] [Abstract][Full Text] [Related]
2. Detailed mapping of chromosome 17p deletions reveals HIC1 as a novel tumor suppressor gene candidate telomeric to TP53 in diffuse large B-cell lymphoma.
Stöcklein H; Smardova J; Macak J; Katzenberger T; Höller S; Wessendorf S; Hutter G; Dreyling M; Haralambieva E; Mäder U; Müller-Hermelink HK; Rosenwald A; Ott G; Kalla J
Oncogene; 2008 Apr; 27(18):2613-25. PubMed ID: 17982487
[TBL] [Abstract][Full Text] [Related]
3. Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas.
Zlamalikova L; Moulis M; Ravcukova B; Liskova K; Malcikova J; Salek D; Jarkovsky J; Svitakova M; Hrabalkova R; Smarda J; Smardova J
Oncol Rep; 2017 Oct; 38(4):2535-2542. PubMed ID: 28791403
[TBL] [Abstract][Full Text] [Related]
4. Differential effect of epigenetic alterations and genomic deletions of CDK inhibitors [p16(INK4a), p15(INK4b), p14(ARF)] in mantle cell lymphoma.
Hutter G; Scheubner M; Zimmermann Y; Kalla J; Katzenberger T; Hübler K; Roth S; Hiddemann W; Ott G; Dreyling M
Genes Chromosomes Cancer; 2006 Feb; 45(2):203-10. PubMed ID: 16258956
[TBL] [Abstract][Full Text] [Related]
5. p53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11;14)(q13;q32).
Louie DC; Offit K; Jaslow R; Parsa NZ; Murty VV; Schluger A; Chaganti RS
Blood; 1995 Oct; 86(8):2892-9. PubMed ID: 7579380
[TBL] [Abstract][Full Text] [Related]
6. Inactivation of the hypermethylated in cancer 1 tumour suppressor--not just a question of promoter hypermethylation?
Jenal M; Britschgi C; Fey MF; Tschan MP
Swiss Med Wkly; 2010; 140():w13106. PubMed ID: 21104471
[TBL] [Abstract][Full Text] [Related]
7. Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional study.
Streich L; Sukhanova M; Lu X; Chen YH; Venkataraman G; Mathews S; Zhang S; Kelemen K; Segal J; Gao J; Gordon L; Chen Q; Behdad A
Genes Chromosomes Cancer; 2020 Aug; 59(8):484-494. PubMed ID: 32277542
[TBL] [Abstract][Full Text] [Related]
8. Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma.
Dreyling MH; Bullinger L; Ott G; Stilgenbauer S; Müller-Hermelink HK; Bentz M; Hiddemann W; Döhner H
Cancer Res; 1997 Oct; 57(20):4608-14. PubMed ID: 9377576
[TBL] [Abstract][Full Text] [Related]
9. [Chromosome arm 17p13.3: could HIC1 be the one ?].
Chopin V; Leprince D
Med Sci (Paris); 2006 Jan; 22(1):54-61. PubMed ID: 16386221
[TBL] [Abstract][Full Text] [Related]
10. ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients.
Mareckova A; Malcikova J; Tom N; Pal K; Radova L; Salek D; Janikova A; Moulis M; Smardova J; Kren L; Mayer J; Trbusek M
Leuk Lymphoma; 2019 Jun; 60(6):1420-1428. PubMed ID: 30626249
[TBL] [Abstract][Full Text] [Related]
11. Clinical aspects of TP53 gene inactivation in diffuse large B-cell lymphoma.
Voropaeva EN; Pospelova TI; Voevoda MI; Maksimov VN; Orlov YL; Seregina OB
BMC Med Genomics; 2019 Mar; 12(Suppl 2):35. PubMed ID: 30871527
[TBL] [Abstract][Full Text] [Related]
12. Mantle cell lymphoma-variant Richter syndrome: Detailed molecular-cytogenetic and backtracking analysis reveals slow evolution of a pre-MCL clone in parallel with CLL over several years.
Klener P; Fronkova E; Berkova A; Jaksa R; Lhotska H; Forsterova K; Soukup J; Kulvait V; Vargova J; Fiser K; Prukova D; Alam M; Calvin Lenyeletse Maswabi B; Michalova K; Zemanova Z; Jancuskova T; Pekova S; Trneny M
Int J Cancer; 2016 Nov; 139(10):2252-60. PubMed ID: 27407063
[TBL] [Abstract][Full Text] [Related]
13. Signification of Hypermethylated in Cancer 1 (HIC1) as Tumor Suppressor Gene in Tumor Progression.
Zheng J; Xiong D; Sun X; Wang J; Hao M; Ding T; Xiao G; Wang X; Mao Y; Fu Y; Shen K; Wang J
Cancer Microenviron; 2012 Dec; 5(3):285-93. PubMed ID: 22528874
[TBL] [Abstract][Full Text] [Related]
14. Association between HIC1 and RASSF1A promoter hypermethylation with MTHFD1 G1958A polymorphism and clinicopathological features of breast cancer in Iranian patients.
Rasti M; Tavasoli P; Monabati A; Entezam M
Iran Biomed J; 2009 Oct; 13(4):199-206. PubMed ID: 19946345
[TBL] [Abstract][Full Text] [Related]
15. Analysis of an independent tumor suppressor locus telomeric to Tp53 suggested Inpp5k and Myo1c as novel tumor suppressor gene candidates in this region.
Hedberg Oldfors C; Dios DG; Linder A; Visuttijai K; Samuelson E; Karlsson S; Nilsson S; Behboudi A
BMC Genet; 2015 Jul; 16():80. PubMed ID: 26170120
[TBL] [Abstract][Full Text] [Related]
16. Identification of the p53 family-responsive element in the promoter region of the tumor suppressor gene hypermethylated in cancer 1.
Britschgi C; Rizzi M; Grob TJ; Tschan MP; Hügli B; Reddy VA; Andres AC; Torbett BE; Tobler A; Fey MF
Oncogene; 2006 Mar; 25(14):2030-9. PubMed ID: 16301995
[TBL] [Abstract][Full Text] [Related]
17. Promoter methylation of PARG1, a novel candidate tumor suppressor gene in mantle-cell lymphomas.
Ripperger T; von Neuhoff N; Kamphues K; Emura M; Lehmann U; Tauscher M; Schraders M; Groenen P; Skawran B; Rudolph C; Callet-Bauchu E; van Krieken JH; Schlegelberger B; Steinemann D
Haematologica; 2007 Apr; 92(4):460-8. PubMed ID: 17488656
[TBL] [Abstract][Full Text] [Related]
18. Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling.
Beà S; Salaverria I; Armengol L; Pinyol M; Fernández V; Hartmann EM; Jares P; Amador V; Hernández L; Navarro A; Ott G; Rosenwald A; Estivill X; Campo E
Blood; 2009 Mar; 113(13):3059-69. PubMed ID: 18984860
[TBL] [Abstract][Full Text] [Related]
19. Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group.
Le Bris Y; Magrangeas F; Moreau A; Chiron D; Guérin-Charbonnel C; Theisen O; Pichon O; Canioni D; Burroni B; Maisonneuve H; Thieblemont C; Oberic L; Gyan E; Pellat-Deceunynck C; Hermine O; Delfau-Larue MH; Tessoulin B; Béné MC; Minvielle S; Le Gouill S
Hematol Oncol; 2020 Oct; 38(4):446-455. PubMed ID: 32472610
[TBL] [Abstract][Full Text] [Related]
20. Prognostic and diagnostic relevance of hypermethylated in cancer 1 (HIC1) CpG island methylation in renal cell carcinoma.
Eggers H; Steffens S; Grosshennig A; Becker JU; Hennenlotter J; Stenzl A; Merseburger AS; Kuczyk MA; Serth J
Int J Oncol; 2012 May; 40(5):1650-8. PubMed ID: 22327210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
